PATENT CLAIM ANALYSIS

Application Number: 16262476
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-07
Patent Classification: ["514", "547000"]

Abstract:
The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (1): and the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 2 ′, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Claim (Index 8):
The method of  claim 1 , wherein the compound is:

Metadata:
- Claim Count in Document: 2.0
- Percentile: 99.0
- Lexical Diversity: 1.78667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15885147', '15885258', '16103375', '15705200', '14394463']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7610437712349255
- 35 USC 102 Novelty (BERT): 0.5575688594268963
- Combined Prediction Score: 0.7406962800541226
- Mean Citation Score: 313.5156780000001
- Max Citation Score: 422.96533
- Similarity Product: 366.2278216421837

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test